CN114173765A - 用于治疗性治疗的包含加波沙朵的药物制剂 - Google Patents

用于治疗性治疗的包含加波沙朵的药物制剂 Download PDF

Info

Publication number
CN114173765A
CN114173765A CN202080051393.2A CN202080051393A CN114173765A CN 114173765 A CN114173765 A CN 114173765A CN 202080051393 A CN202080051393 A CN 202080051393A CN 114173765 A CN114173765 A CN 114173765A
Authority
CN
China
Prior art keywords
gaboxadol
pharmaceutically acceptable
acceptable salt
drug
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080051393.2A
Other languages
English (en)
Chinese (zh)
Inventor
马修·杜林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Priority to CN202410172907.XA priority Critical patent/CN118141810A/zh
Publication of CN114173765A publication Critical patent/CN114173765A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080051393.2A 2019-07-15 2020-07-15 用于治疗性治疗的包含加波沙朵的药物制剂 Pending CN114173765A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410172907.XA CN118141810A (zh) 2019-07-15 2020-07-15 用于治疗性治疗的包含加波沙朵的药物制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874152P 2019-07-15 2019-07-15
US62/874,152 2019-07-15
PCT/US2020/042044 WO2021011597A1 (en) 2019-07-15 2020-07-15 Pharmaceutical formulations containing gaboxadol for therapeutic treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410172907.XA Division CN118141810A (zh) 2019-07-15 2020-07-15 用于治疗性治疗的包含加波沙朵的药物制剂

Publications (1)

Publication Number Publication Date
CN114173765A true CN114173765A (zh) 2022-03-11

Family

ID=74211193

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080051393.2A Pending CN114173765A (zh) 2019-07-15 2020-07-15 用于治疗性治疗的包含加波沙朵的药物制剂
CN202410172907.XA Pending CN118141810A (zh) 2019-07-15 2020-07-15 用于治疗性治疗的包含加波沙朵的药物制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410172907.XA Pending CN118141810A (zh) 2019-07-15 2020-07-15 用于治疗性治疗的包含加波沙朵的药物制剂

Country Status (10)

Country Link
US (3) US20210015760A1 (https=)
EP (1) EP3982937A4 (https=)
JP (1) JP2022540917A (https=)
KR (1) KR20220035195A (https=)
CN (2) CN114173765A (https=)
AU (1) AU2020313930A1 (https=)
CA (1) CA3146737A1 (https=)
IL (1) IL289657A (https=)
MX (1) MX2022000663A (https=)
WO (1) WO2021011597A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9446028B2 (en) * 2014-06-06 2016-09-20 Ovid Therapeutics Inc Methods of increasing tonic inhibition and treating fragile X syndrome and angelman syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2951497C (en) * 2014-06-12 2019-04-09 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity
EP4541420A3 (en) * 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US20170348232A1 (en) * 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
EP3481387A4 (en) * 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
CN110225754A (zh) * 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9446028B2 (en) * 2014-06-06 2016-09-20 Ovid Therapeutics Inc Methods of increasing tonic inhibition and treating fragile X syndrome and angelman syndrome

Also Published As

Publication number Publication date
MX2022000663A (es) 2022-02-16
US20220040120A1 (en) 2022-02-10
IL289657A (en) 2022-03-01
WO2021011597A1 (en) 2021-01-21
US20240252447A1 (en) 2024-08-01
CN118141810A (zh) 2024-06-07
CA3146737A1 (en) 2021-01-21
EP3982937A1 (en) 2022-04-20
AU2020313930A1 (en) 2022-02-03
KR20220035195A (ko) 2022-03-21
JP2022540917A (ja) 2022-09-20
EP3982937A4 (en) 2022-08-10
US20210015760A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
EP2688557B1 (en) Methods and compositions for treatment of attention deficit disorder
AU2005307052B2 (en) Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane
ES2699077T3 (es) Apomorfina sublingual
JP3511074B2 (ja) ニコチン依存症治療のための薬学的処方
JPH11511162A (ja) ドーパミン作用物質のための経口速溶性組成物
ES2930899T3 (es) Monohidrato de gaboxadol en el tratamiento del tinnitus
SK283301B6 (sk) Použitie farmaceutickej zmesi na ústne podanie
JP2011515485A (ja) ロフェキシジンを経粘膜送達するための組成物およびその方法
JP2008540437A (ja) キニーネを含有する制御放出調合剤
US20100113453A1 (en) Sublingual Formulations of D-Cycloserine and Methods of Using Same
JP4287596B2 (ja) ニコチン依存症の治療のためのデオキシペガニン含有医薬組成物
US20240252447A1 (en) Pharmaceutical formulations containing gaboxadol for therapeutic treatment
ES2828034T3 (es) Minicomprimidos de melatonina y método de fabricación de los mismos
AU2018285927B2 (en) Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders
TW200800155A (en) Gastric retentive gabapentin dosage forms and methods for using same
JP2007509031A (ja) ガランタミンの口腔用製剤およびその使用
US11364228B2 (en) Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
WO2021231582A1 (en) Nitro-aminoadamantane compounds for the treatment of negative symptoms and cognitive impairment associated with schizophrenia
CN113423399A (zh) 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
HK40031715A (en) Use of gaboxadol in the treatment of narcolepsy
Saudagar et al. Review on Pulsatile Drug Delivery System

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220311

WD01 Invention patent application deemed withdrawn after publication